Celon PharmaLTS:0RKX 48 PB Ratio is 2.29 as of Jul. 07, 2026, which is 27% below its 10-year median of 3.13. GuruFocus rates LTS:0RKX with a GF Score™ of 48/100 and a GF Value™ of zł26.17. The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Celon Pharma ranks worse than 52.01% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Celon Pharma's share price is zł22.50. Celon Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was zł9.82. Hence, Celon Pharma's PB Ratio of today is 2.29.
Good Sign:
Celon Pharma SA stock PB Ratio (=2.01) is close to 1-year low of 2.01.
The historical rank and industry rank for Celon Pharma's PB Ratio or its related term are showing as below:
LTS:0RKX'
s PB Ratio Range Over the Past 10 Years
Min: 1.26 Med: 3.13 Max: 6.74
Current: 2.01
During the past 11 years, Celon Pharma's highest PB Ratio was 6.74. The lowest was 1.26. And the median was 3.13.
LTS:0RKX's PB Ratio is ranked worse than 52.01% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs LTS:0RKX: 2.01
During the past 12 months, Celon Pharma's average Book Value Per Share Growth Rate was 26.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.60% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Celon Pharma was 64.50% per year. The lowest was -11.40% per year. And the median was 0.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Celon Pharma PB Ratio Related Terms
Celon Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Celon Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Celon Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Celon Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Celon Pharma (LTS:0RKX) has a PB Ratio of 2.29 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Celon Pharma and its competitors. This is 27% below median its historical median of 3.13. Over the past decade, Celon Pharma's PB Ratio has ranged from 1.26 to 6.74. According to the industry distribution chart, Celon Pharma ranks #479 out of 921 companies in the Drug Manufacturers industry, placing it in the top 52%.
Is Celon Pharma's PB Ratio too high?
Celon Pharma's current PB Ratio of 2.29 is 27% below median its 10-year median of 3.13. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 6.74. The Drug Manufacturers industry median PB Ratio is 1.93. Celon Pharma's value of 2.29 is 18.7% above this industry median. Based on the distribution chart, Celon Pharma ranks #479 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Celon Pharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #479 out of 921 companies for PB Ratio. This places Celon Pharma in the lower half of its industry. The industry median PB Ratio is 1.93. Celon Pharma's value of 2.29 is 18.7% above this benchmark. Historically, Celon Pharma's own PB Ratio has ranged from 1.26 to 6.74 over the past decade. While the company's 10-year median is 3.13 vs. the industry median of 1.93, Celon Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.93, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current PB Ratio of 2.29 is 18.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current PB Ratio is 2.29, which is 27% below median its own 10-year median of 3.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current PB Ratio of 2.29. The stock's GF Value™ is zł26.17, compared to a current price of zł22.50 — trading 14% below its estimated fair value. The current PB Ratio is 2.29, which is 27% below median its 10-year median of 3.13 and 18.7% above the Drug Manufacturers industry median of 1.93. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current PB Ratio is 2.29 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (LTS:0RKX) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł22.50 is trading 14% below its estimated GF Value™ of zł26.17.
Key valuation signals for LTS:0RKX:
PB Ratio: 2.29 (27% below median its 10-year median of 3.13)
GF Value™: zł26.17 vs. price of zł22.50 (14% below fair value)
Industry Position: 18.7% above the Drug Manufacturers median (#479 of 921)
No single metric tells the full story. See the LTS:0RKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score
Get the complete analysis for LTS:0RKX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 
